Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 120

Sort by

Sort Order Select

Journal Articles

A Multi-Center, Multinational, Prospective Observational Registry Study of Defibrotide in Patients Diagnosed with Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT)

Mohamad Mohty, MD PhD, Marta Lisa Battista, Didier Blaise, MD PhD, Elisabetta Calore, MD, Simone Cesaro, Adam Gassas, Natalia Maximova, Katia Perruccio, Cecile Renard, MD, Robert Wynn, Marco Zecca, Myriam Labopin, MD, Raj Hanvesakul, Robert J. Ryan, MS, Fabio Ciceri, MD, Sarah Lawson, MD

Blood (2019) 134 (Supplement_1): 1972.

https://doi.org/10.1182/blood-2019-123529

Published: 2019

Journal Articles

Home Treatment of Bortezomib: A Preliminary Exploration of a New Treatment Mode in China

Congli Zhang, Xin-xin Cao, Dong-zhu Li, Jun Feng, MD, Lu Zhang, MD, Yan Zhang, Ming-hui Duan, MD, Miao Chen, MD, Chen Yang, Wei Wang, Dao-Bin Zhou, Jian Li, MD

Blood (2019) 134 (Supplement_1): 2127.

https://doi.org/10.1182/blood-2019-125505

Published: 2019

Journal Articles

Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Christopher Pleyer, MD, Jeffrey Cohen, MD, Susan Soto, Mir Ali, PhD, Inhye E Ahn, MD, Pia Nierman, BSN, MA, RN, Janet Valdez, Jennifer Lotter, PA-C, Jeanine Superata, RN, Xin Tian, Adrian Wiestner, MD PhD, Clare Sun, MD

Blood (2019) 134 (Supplement_1): 3053.

https://doi.org/10.1182/blood-2019-121675

Published: 2019

Journal Articles

Intravenous Iron Promotes Low-Grade Inflammation in Anemic Patients By Triggering Macrophage Activation

Francesca Vinchi, PhD, Annalisa Castagna, B.S., PhD, Milene Costa da Silva, Fabiana Busti, MD PhD, Giacomo Marchi, MD, Richard Sparla, Martina U. Muckenthaler, PhD, Domenico Girelli, MD, PhD

Blood (2019) 134 (Supplement_1): 957.

https://doi.org/10.1182/blood-2019-132235

Published: 2019

Journal Articles

Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)

Amrita Y. Krishnan, MD, Krina K. Patel, MD MSc, Parameswaran Hari, MBBS, MD, Sundar Jagannath, MD, Ruben Niesvizky, MD, Rebecca W. Silbermann, MD, Deborah Berg, RN, MSN, Jianchang Lin, PhD, Eric Robert Fedyk, BSc, MSc, PhD, Antonio Palumbo, MD, Keith E. Stockerl-Goldstein, MD

Blood (2019) 134 (Supplement_1): 140.

https://doi.org/10.1182/blood-2019-128007

Published: 2019

Journal Articles

Use of Pegylated Interferon in Six Pediatric Patients with Myeloproliferative Neoplasms

Nicole Kucine, MD, Shayla Bergmann, MD, Spencer Krichevsky, BS, Devin Jones, MS, Michael E. Rytting, MD, Linda Resar, MD, John Mascarenhas, MD, Srdan Verstovsek, MD PhD, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 4194.

https://doi.org/10.1182/blood-2019-124023

Published: 2019

Journal Articles

Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

Kelly S. Chien, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Naval G. Daver, MD, Jorge E. Cortes, MD, Courtney D. DiNardo, MDMSc, Elias Jabbour, MD, Michael Andreeff, MD PhD, Yesid Alvarado, MD, Prithviraj Bose, MD, Nitin Jain, MD, Kimberly Sheppard, BSN, RN, Cheri Klingner-Winton, Sherry A. Pierce, BSN, BA, Xiao Qin Dong, Kelly Soltysiak, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4240.

https://doi.org/10.1182/blood-2019-129598

Published: 2019

Journal Articles

Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update

Blood (2019) 134 (Supplement_1): 3152.

https://doi.org/10.1182/blood-2019-123560

Published: 2019

Journal Articles

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody ® -CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Pieternella Lugtenburg, MD PhD, Rogier Mous, MD PhD, Michael Roost Clausen, Martine E.D. Chamuleau, Peter Johnson, MDFRCP, Kim Linton, PhD, Simon Rule, Roberto S Oliveri, MD PhD, Dena DeMarco, Ida H Hiemstra, PhD, Guang Chen, Ada Azaryan, Manish Gupta, Tahamtan Ahmadi, Martin Hutchings, MD PhD

Blood (2019) 134 (Supplement_1): 758.

https://doi.org/10.1182/blood-2019-121460

Published: 2019

Journal Articles

Prospective, Multi-Center, Phase I Clinical Trial of PLX-R18 Placental Expanded Adherent Stromal Cells in Subjects with Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation

Hillard M Lazarus, MD, Leland Metheny, MD, Tsila Zuckerman, MD, Carolina Escobar, MD, Joseph P. McGuirk, DO, Yael Rosen, MD, Jacob M. Rowe, MD

Blood (2018) 132 (Supplement 1): 3379.

https://doi.org/10.1182/blood-2018-99-116239

Published: 2018

Journal Articles

Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia A without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study)

Midori Shima, MD PhD, Keiji Nogami, MDPhD, Sayaka Nagami, BSc, Seitaro Yoshida, PhD, Koichiro Yoneyama, MSc, Akira Ishiguro, MD PhD, Takashi Suzuki, MD PhD, Masashi Taki, MD PhD

Blood (2018) 132 (Supplement 1): 1186.

https://doi.org/10.1182/blood-2018-99-115792

Published: 2018

Journal Articles

Preliminary Results from a Phase II Study of the Combination of Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

Kelly S. Chien, MD, Jorge E. Cortes, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MD, MSc, Naval G. Daver, MD, Nitin Jain, MD, Kiran Naqvi, MD, MPH, Elias J. Jabbour, MD, Kimberly B. Sheppard, RN, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2018) 132 (Supplement 1): 464.

https://doi.org/10.1182/blood-2018-99-115720

Published: 2018

Journal Articles

Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product

Michael P. Rettig, PhD, Geoffrey L. Uy, MD, Asad Bashey, MD PhD, Steven Devine, Samantha Jaglowski, MDMPH, Abi Vainstein, MD, Ella Sorani, PhD, Hemda Chen, PharmD, Osnat Bohana-Kashtan, PhD, Stephen Shaw, PhD, Peter Westervelt, MDPhD, John F. DiPersio, MD PhD

Blood (2018) 132 (Supplement 1): 118.

https://doi.org/10.1182/blood-2018-99-109701

Published: 2018

Journal Articles

Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies

Ido Paz-Priel, Tiffany Chang, Elina Asikanius, Sammy Chebon, Thomas Emrich, Elena Fernandez, Peter Kuebler, Christophe Schmitt

Blood (2018) 132 (Supplement 1): 633.

https://doi.org/10.1182/blood-2018-99-118492

Published: 2018

Journal Articles

HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors

Guy Young, Robert F. Sidonio, Ri Liesner, Johannes Oldenburg, Tiffany Chang, Marianne Uguen, Christophe Dhalluin, Christophe Schmitt, Gallia G. Levy, Midori Shima, MDPhD, Johnny Mahlangu

Blood (2017) 130 (Supplement 1): 85.

https://doi.org/10.1182/blood.V130.Suppl_1.85.85

Published: 2017

Journal Articles

Phase 1/2 Trial of Subcutaneously Administered Factor IX Variant CB2679d/ISU304: Pharmacokinetics and Activity

Chur Woo You, MDPhD, Ho-Jin Shin, MD, Howard Levy, MBBCh, PhD, Martin Lee, PhD, Seung-Beom Hong, PhD, Jamie Ellen Siegel, MD, June Young Park, MD

Blood (2017) 130 (Supplement 1): 87.

https://doi.org/10.1182/blood.V130.Suppl_1.87.87

Published: 2017

Journal Articles

A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Patients with Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN (The Bloodwise / TAP PHAZAR Study on Behalf of the UK MPN CSG)

Mark W Drummond, MB ChB, PhD FRCPath, Claire N. Harrison, BMBCh, DM, FRCP, FRCPath, Samuel Munoz Vicente, MSc, Adam J Mead, MD PhD, Christina Yap, MSci, PhD CStat, Frederick Chen, FRCP, FRCPath, PhD, Srinivasan Narayanan, MBBS, MRCP, FRCPath, Dragana Milojkovic, MBBS, PhD, Leyre Navarro-Nunez, PhD, Steven Knapper, BMBCh, MRCP, MRCPath, DM

Blood (2017) 130 (Supplement 1): 1649.

https://doi.org/10.1182/blood.V130.Suppl_1.1649.1649

Published: 2017

Journal Articles

Coversin, a Novel C5 Complement Inhibitor, Is Safe and Effective in the Treatment of PNH: Results of a Phase II Clinical Trial

Anita Hill, MBChB (Hons), PhD, Wynne Weston-Davies, MB FRCS, Miles Nunn, PhD, Tadeusz Robak, MD PhD, Jerzy Windyga, MD, Andrzej Hellmann, MD PhD DSc, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Agniezka Piekarska, Anna Szmigielska-Kaplon, Morag Griffin, Talha Munir

Blood (2017) 130 (Supplement 1): 4747.

https://doi.org/10.1182/blood.V130.Suppl_1.4747.4747

Published: 2017

Journal Articles

Vaccination with a DNA and MVA ‘Prime-Boost’ Regimen Induces Strong CD8 + T-Cell Responses Against the Immunodominant Minor Histocompatibility Antigen, HA-1: Results of a First-in-Man Phase I Clinical Trial

Charlotte F Inman, BVSc, PhD, Suzy A Eldershaw, BSc. (Hons.), PhD, Hayden Pearce, BSc. (Hons.), PhD, Ben E Abbotts, BSc. (Hons.), MSc., Mirjana Sirovica, BSc(Hons), MSc, Paul Ferguson, MD PhD MRCP, Donna L Walsh, Dip(HE), BSc., Jane Nunnick, BSC. (Hons.), MSc., Shamyla Siddique, BSc.(Hons.), MPhil, Paul Moss, MBBS, PhD FRCP, Ram K Malladi, FRCPath

Blood (2017) 130 (Supplement 1): 1908.

https://doi.org/10.1182/blood.V130.Suppl_1.1908.1908

Published: 2017

Journal Articles

A Phase 2 Trial of Early Intervention with Ibrutinib in Patients with Asymptomatic, High-Risk CLL

Farrukh T. Awan, MD MS, Shanmugapriya Thangavadivel, PhD, David Weiss, Lai Wei, PhD, Jennifer A. Woyach, MD, Kerry A. Rogers, MD, Jeffrey Jones, MD, Leslie Andritsos, MD, Natarajan Muthusamy, DVM,PhD, Barbara Andersen, PhD, John C. Byrd, MD

Blood (2017) 130 (Supplement 1): 1748.

https://doi.org/10.1182/blood.V130.Suppl_1.1748.1748

Published: 2017

NARROW

A Multi-Center, Multinational, Prospective Observational Registry Study of Defibrotide in Patients Diagnosed with Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT)

Home Treatment of Bortezomib: A Preliminary Exploration of a New Treatment Mode in China

Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Intravenous Iron Promotes Low-Grade Inflammation in Anemic Patients By Triggering Macrophage Activation

Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)

Use of Pegylated Interferon in Six Pediatric Patients with Myeloproliferative Neoplasms

Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody ® -CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Prospective, Multi-Center, Phase I Clinical Trial of PLX-R18 Placental Expanded Adherent Stromal Cells in Subjects with Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation

Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia A without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study)

Preliminary Results from a Phase II Study of the Combination of Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product

Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies

HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors

Phase 1/2 Trial of Subcutaneously Administered Factor IX Variant CB2679d/ISU304: Pharmacokinetics and Activity

Coversin, a Novel C5 Complement Inhibitor, Is Safe and Effective in the Treatment of PNH: Results of a Phase II Clinical Trial

Vaccination with a DNA and MVA ‘Prime-Boost’ Regimen Induces Strong CD8 + T-Cell Responses Against the Immunodominant Minor Histocompatibility Antigen, HA-1: Results of a First-in-Man Phase I Clinical Trial

A Phase 2 Trial of Early Intervention with Ibrutinib in Patients with Asymptomatic, High-Risk CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only